These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 16278304

  • 21. The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
    Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bi C, Ong KO, Zeng Q, Chng WJ.
    Mol Cancer; 2012 Sep 21; 11():72. PubMed ID: 22995644
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.
    Alvira D, Naughton R, Bhatt L, Tedesco S, Landry WD, Cotter TG.
    J Biol Chem; 2011 Sep 16; 286(37):32313-23. PubMed ID: 21795709
    [Abstract] [Full Text] [Related]

  • 23. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, Zhou H, Qu L.
    Sci China Life Sci; 2018 Sep 16; 61(9):999-1009. PubMed ID: 30054832
    [Abstract] [Full Text] [Related]

  • 24. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL.
    Blood; 2005 May 15; 105(10):3995-4003. PubMed ID: 15657179
    [Abstract] [Full Text] [Related]

  • 25. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X, Tu H, Yang Y, Jiang X, Hu X, Luo Q, Li J.
    J Biol Chem; 2019 Aug 09; 294(32):12167-12179. PubMed ID: 31235520
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 09; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 30. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
    Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.
    J Hematol Oncol; 2014 Apr 28; 7():37. PubMed ID: 24775308
    [Abstract] [Full Text] [Related]

  • 31. BCR-ABL affects STAT5A and STAT5B differentially.
    Schaller-Schönitz M, Barzan D, Williamson AJ, Griffiths JR, Dallmann I, Battmer K, Ganser A, Whetton AD, Scherr M, Eder M.
    PLoS One; 2014 Apr 28; 9(5):e97243. PubMed ID: 24836440
    [Abstract] [Full Text] [Related]

  • 32. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S, Holtz M, Gupta M, Bhatia R.
    Blood; 2004 Apr 15; 103(8):3167-74. PubMed ID: 15070699
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY, Sun GB, Wang YJ, Yan F.
    Biol Pharm Bull; 2020 Apr 15; 43(10):1526-1533. PubMed ID: 32999163
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
    Koldehoff M, Elmaagacli AH.
    Methods Mol Biol; 2009 Apr 15; 487():451-66. PubMed ID: 19301661
    [Abstract] [Full Text] [Related]

  • 38. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
    Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R.
    Leukemia; 2008 Apr 15; 22(4):748-55. PubMed ID: 18273048
    [Abstract] [Full Text] [Related]

  • 39. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
    Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM.
    Cancer Res; 2019 Sep 15; 79(18):4744-4753. PubMed ID: 31311809
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.